CoImmune company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

coimmune.com

Founded Year

1997

Stage

Unattributed VC | Alive

Total Raised

$240.07M

Last Raised

$45M | 2 yrs ago

Revenue

$0000 

About CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

CoImmune Headquarters Location

4233 Technology Drive

Durham, North Carolina, 27704,

United States

919-287-6300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CoImmune

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CoImmune is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CoImmune Patents

CoImmune has filed 49 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/20/2016

2/15/2022

Clusters of differentiation, Immunology, Immune system, Cytokines, Transcription factors

Grant

Application Date

12/20/2016

Grant Date

2/15/2022

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Cytokines, Transcription factors

Status

Grant

Latest CoImmune News

CAR-T SEAKER Cells Activate Small Molecule Drugs at Tumor Site

Jan 3, 2022

January 3, 2022 Chimeric antigen receptor (CAR)-T cells have broadened treatment options for some cancers—particularly certain types of blood cancers. But they have limitations: 1) variable antigen expression patterns on cancer cells can lead to “escape” from the therapy, 2) CAR-T cells can become “exhausted” and even inhibited by the cancer cells themselves, and 3) immunosuppressive tumor microenvironments lead to lack of efficacy against dense solid tumors. Now, scientists have developed a new type of CAR-T cells that act as a “micropharmacy.” The cells co-express bacterial enzymes that activate prodrugs at the disease site, killing both tumor cells that contain the cancer marker as well as nearby cancer cells that do not. What’s more, the engineered cells can produce the drug even after they become exhausted, and the drug is not suppressed by the cancer. “We call them SEAKER cells,” said David Scheinberg, MD, PhD, chair of the molecular pharmacology program at Memorial Sloan Kettering Cancer Center’s Sloan Kettering Institute (SKI). “SEAKER stands for Synthetic Enzyme-Armed KillER cells. These cells combine the target-seeking power of immune cells with the ability to locally generate a potent anticancer drug for double effect.” The idea of using CAR-T cells to deliver additional therapeutic agents isn’t new. Several research groups have shown it’s possible to get the cells to make immune proteins like antibodies and cytokines. But getting CAR-T cells to produce a small-molecule cancer drug is more challenging. The molecule used in the study, called AMS, is too powerful to be injected directly into an animal’s bloodstream. But when it is produced locally at the site of a tumor, it is effective at safely killing cancer cells in mice. The scientists have not yet tested the technology in people. The team linked the cancer drug to another chemical that “masks” its function. Then, they genetically engineered the T cells to make an enzyme that cuts the masking molecule from the drug. When the prodrug is injected into the bloodstream, it circulates through the body. The enzyme produced by the CAR-T cells releases the active part of the prodrug at the site of the tumor. The scientists tested their SEAKER cells on both cancer cells in culture and in mouse models. In both cases, the SEAKER cells performed better than regular CAR-T cells at killing the cancer cells. “It’s one of the wildest ideas I’ve ever worked on,” said Derek Tan, PhD, chair of the chemical biology program at the SKI. “It’s very exciting that we got it to work.” The technology has been licensed by the company CoImmune to develop the CAR-T cell technology for human trials. “There is an opportunity to better understand the limitations of CAR-T cells and specifically engineer new treatment options that have the potential to address challenges with eliminating tumor masses and toxicity,” said Charles Nicolette, PhD, CEO of CoImmune. “The collaboration with CoImmune is exciting because we need a company to take this on to scale up and manufacture a standardized product,” Scheinberg added. Another part of the appeal of the SEAKER technology is that it has more than one possible application. “You could imagine it being used to produce drugs to fight other conditions, such as autoimmune diseases and infections,” Scheinberg said. But for now, the focus of the MSK researchers and CoImmune will be on cancer. Scheinberg speculates that a clinical trial in cancer is about two to three years away. Share

CoImmune Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CoImmune Rank

  • When was CoImmune founded?

    CoImmune was founded in 1997.

  • Where is CoImmune's headquarters?

    CoImmune's headquarters is located at 4233 Technology Drive, Durham.

  • What is CoImmune's latest funding round?

    CoImmune's latest funding round is Unattributed VC.

  • How much did CoImmune raise?

    CoImmune raised a total of $240.07M.

  • Who are the investors of CoImmune?

    Investors of CoImmune include Dr. Lucio Rovati, DSC Investment, Brain Asset Management, Magna Investment, Korea Investment Partners and 42 more.

  • Who are CoImmune's competitors?

    Competitors of CoImmune include GeoVax, Humanetics, ISA Pharmaceuticals, FirstString Research, Lead Pharma, Aquinox Pharmaceuticals, Histogen, Curetis, Bicycle Therapeutics, Immune Design and 49 more.

You May Also Like

T
Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

I
ImmuRx

ImmuRx is focused on cancer and chronic infectious disease by stimulating both the innate and adaptive halves of the immune system. Per the company, ImmuRx has demonstrated significantly greater immune responses and greater therapeutic benefit than most competing adjuvants in a wide variety of disease indications.

I
Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

J
JadoLabs

JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.